Humana stock snapshot after recent performance shift

Humana (HUM) has drawn investor attention after a recent share price move, with the stock closing at US$307.95 and showing double digit total returns over the past year and past 3 years.

The recent 30 day share price return of 43.08% and 90 day share price return of 69.99% contrast with a 3 year total shareholder return that is down 35.72%. This suggests near term momentum following a tougher longer stretch.

If Humana’s rebound has you rethinking your watchlist, it can be useful to see what else is gaining attention in healthcare. This includes companies using AI in care delivery and diagnostics through the 34 healthcare AI stocks.

With Humana trading at US$307.95 and carrying an intrinsic value estimate that implies a 68.08% discount, yet sitting above some analyst targets, you have to ask: is there still a potential entry point here, or is the market already pricing in future growth?

Most Popular Narrative: 44.7% Overvalued

Humana’s last close at $307.95 sits well above the narrative fair value of $212.87, which, according to yiannisz, reflects pressure from tightening Medicare oversight and compliance demands.

Humana’s current pressures underscore that reality. As Medicare Advantage continues to expand, the companies that thrive will likely be those that treat compliance not as a checkbox, but as an operational framework embedded into every layer of their billing and clinical review systems.

Want to see how an insurer with more than $137.2b in revenue ends up with this valuation gap? The narrative leans on modest revenue assumptions, shifting profit margins and a future earnings multiple that could surprise anyone only looking at recent net income.

Result: Fair Value of $212.87 (OVERVALUED)

However, this overvaluation story could shift if Medicare oversight softens or if Humana’s revenue growth and profit margins differ materially from the narrative’s assumptions.

Another View on Humana’s Valuation

While the community narrative pegs Humana as 44.7% overvalued at $307.95 versus a fair value of $212.87, the SWS DCF model points the other way, with a future cash flow value estimate of $964.87, implying the stock trades at a large discount. Which perspective aligns better with the level of risk you are willing to take?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Humana for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Conflicted by the mix of risks and rewards across this article? Act while the details are still fresh in your mind and weigh the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you might miss opportunities that fit your style even better, so put the screener to work and widen your options.

• Spot potential bargains trading below intrinsic estimates by checking out 49 high quality undervalued stocks.
• Build an income focused shortlist with reliable payouts using the 10 dividend fortresses.
• Prioritise financial resilience by scanning companies through the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.